Cargando…

Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice

Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Aastha, Bhuria, Vikas, Hazari, Puja P., Pathak, Uma, Mathur, Sweta, Roy, Bal G., Sandhir, Rajat, Soni, Ravi, Dwarakanath, Bilikere S., Bhatt, Anant N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928292/
https://www.ncbi.nlm.nih.gov/pubmed/29740320
http://dx.doi.org/10.3389/fphar.2018.00394
_version_ 1783319213555843072
author Arora, Aastha
Bhuria, Vikas
Hazari, Puja P.
Pathak, Uma
Mathur, Sweta
Roy, Bal G.
Sandhir, Rajat
Soni, Ravi
Dwarakanath, Bilikere S.
Bhatt, Anant N.
author_facet Arora, Aastha
Bhuria, Vikas
Hazari, Puja P.
Pathak, Uma
Mathur, Sweta
Roy, Bal G.
Sandhir, Rajat
Soni, Ravi
Dwarakanath, Bilikere S.
Bhatt, Anant N.
author_sort Arora, Aastha
collection PubMed
description Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from the toxic effects of radiation and BLM, its application is limited due to associated toxicity and unfavorable route of administration. Therefore, there is a need for selective, potent, and safe anti-fibrotic drugs. The current study was undertaken to assess the protective effects of DRDE-30, an analog of Amifostine, on BLM-induced lung injury in C57BL/6 mice. Whole body micro- computed tomography (CT) was used to non-invasively observe tissue damage, while broncheo-alveolar lavage fluid (BALF) and lung tissues were assessed for oxidative damage, inflammation and fibrosis. Changes in the lung density revealed by micro-CT suggested protection against BLM-induced lung injury by DRDE-30, which correlated well with changes in lung morphology and histopathology. DRDE-30 significantly blunted BLM-induced oxidative stress, inflammation and fibrosis in the lungs evidenced by reduced oxidative damage, endothelial barrier dysfunction, Myeloperoxidase (MPO) activity, pro-inflammatory cytokine release and protection of tissue architecture, that could be linked to enhanced anti-oxidant defense system and suppression of redox-sensitive pro-inflammatory signaling cascades. DRDE-30 decreased the BLM-induced augmentation in BALF TGF-β and lung hydroxyproline levels, as well as reduced the expression of the mesenchymal marker α-smooth muscle actin (α-SMA), suggesting the suppression of epithelial to mesenchymal transition (EMT) as one of its anti-fibrotic effects. The results demonstrate that the Amifostine analog, DRDE-30, ameliorates the oxidative injury and lung fibrosis induced by BLM and strengthen its potential use as an adjuvant in alleviating the side effects of BLM.
format Online
Article
Text
id pubmed-5928292
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59282922018-05-08 Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice Arora, Aastha Bhuria, Vikas Hazari, Puja P. Pathak, Uma Mathur, Sweta Roy, Bal G. Sandhir, Rajat Soni, Ravi Dwarakanath, Bilikere S. Bhatt, Anant N. Front Pharmacol Pharmacology Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from the toxic effects of radiation and BLM, its application is limited due to associated toxicity and unfavorable route of administration. Therefore, there is a need for selective, potent, and safe anti-fibrotic drugs. The current study was undertaken to assess the protective effects of DRDE-30, an analog of Amifostine, on BLM-induced lung injury in C57BL/6 mice. Whole body micro- computed tomography (CT) was used to non-invasively observe tissue damage, while broncheo-alveolar lavage fluid (BALF) and lung tissues were assessed for oxidative damage, inflammation and fibrosis. Changes in the lung density revealed by micro-CT suggested protection against BLM-induced lung injury by DRDE-30, which correlated well with changes in lung morphology and histopathology. DRDE-30 significantly blunted BLM-induced oxidative stress, inflammation and fibrosis in the lungs evidenced by reduced oxidative damage, endothelial barrier dysfunction, Myeloperoxidase (MPO) activity, pro-inflammatory cytokine release and protection of tissue architecture, that could be linked to enhanced anti-oxidant defense system and suppression of redox-sensitive pro-inflammatory signaling cascades. DRDE-30 decreased the BLM-induced augmentation in BALF TGF-β and lung hydroxyproline levels, as well as reduced the expression of the mesenchymal marker α-smooth muscle actin (α-SMA), suggesting the suppression of epithelial to mesenchymal transition (EMT) as one of its anti-fibrotic effects. The results demonstrate that the Amifostine analog, DRDE-30, ameliorates the oxidative injury and lung fibrosis induced by BLM and strengthen its potential use as an adjuvant in alleviating the side effects of BLM. Frontiers Media S.A. 2018-04-24 /pmc/articles/PMC5928292/ /pubmed/29740320 http://dx.doi.org/10.3389/fphar.2018.00394 Text en Copyright © 2018 Arora, Bhuria, Hazari, Pathak, Mathur, Roy, Sandhir, Soni, Dwarakanath and Bhatt. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Arora, Aastha
Bhuria, Vikas
Hazari, Puja P.
Pathak, Uma
Mathur, Sweta
Roy, Bal G.
Sandhir, Rajat
Soni, Ravi
Dwarakanath, Bilikere S.
Bhatt, Anant N.
Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
title Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
title_full Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
title_fullStr Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
title_full_unstemmed Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
title_short Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
title_sort amifostine analog, drde-30, attenuates bleomycin-induced pulmonary fibrosis in mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928292/
https://www.ncbi.nlm.nih.gov/pubmed/29740320
http://dx.doi.org/10.3389/fphar.2018.00394
work_keys_str_mv AT aroraaastha amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT bhuriavikas amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT hazaripujap amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT pathakuma amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT mathursweta amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT roybalg amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT sandhirrajat amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT soniravi amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT dwarakanathbilikeres amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice
AT bhattanantn amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice